References
- Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S.
Reducing the Global Burden of Cardiovascular Disease, Part 2:
Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017 Sep
1;121(6):695-710.
- Montinari MR, Minelli S, De Caterina R.
The first 3500 years
of aspirin history from its roots - A concise summary. Vascul
Pharmacol. 2019 Feb;113:1-8.
- Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of
aspirin against acute myocardial infarction and death in men with
unstable angina. Results of a Veterans Administration Cooperative
Study. N Engl J Med 1983;309(07):396–403.
- Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both
in unstable angina. Results of a Canadian multicenter trial. N Engl J
Med 1985;313(22):1369–1375.
- ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomised trial of intravenous streptokinase, oral aspirin,
both, or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. Lancet 1988;2(8607):349–360.
- Piepoli MF, Hoes AW, Agewall S, et al; ESC Scientific Document Group.
2016 European Guidelines on cardiovascular disease prevention in
clinical practice: the Sixth Joint Task Force of the European Society
of Cardiology and Other Societies on Cardiovascular Disease Prevention
in Clinical Practice (constituted by representatives of 10 societies
and by invited experts): developed with the special contribution of
the European Association for Cardiovascular Prevention &
Rehabilitation (EACPR). Eur Heart J 2016;37(29):2315–2381.
- Cardiovascular disease and risk management: standards of medical care
in diabetes—2019. Diabetes Care. 2019 January. 2018:S86-S104
- Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use
for the primary prevention of cardiovascular disease and colorectal
cancer: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med 2016; 164: 836-45.
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on
the primary prevention of cardiovascular disease: executive summary: a
report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines. J Am Coll
Cardiol 2019;74(10):1376–1414.
- McNeil JJ, Nelson MR, Woods RL, et al; ASPREE Investigator Group.
Effect of aspirin on all-cause mortality in the healthy elderly. N
Engl J Med 2018;379(16):1519–1528.
- Gaziano JM, Brotons C, Coppolecchia R, et al; ARRIVE Executive
Committee. Use of aspirin to reduce risk of initial vascular events in
patients at moderate risk of cardiovascular disease (ARRIVE): a
randomised, double-blind, placebo-controlled trial. Lancet 2018;
392(10152):1036–1046.
- Bowman L, Mafham M, Wallendszus K, et al; ASCEND Study Collaborative
Group. Effects of aspirin for primary prevention in persons with
diabetes mellitus. N Engl J Med 2018;379(16): 1529–1539.
- Oğuzhan
Çelik , Cem Çil , Bülent Özlek , et
al. Design and rationale for the ASSOS study: Appropriateness of
aspirin use in medical outpatients a multicenter and observational
study. Anatol J Cardiol. 2018 Dec;20(6):354-362.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, et al. 2013 ACC/AHA
guideline on the assessment of cardiovascular risk: a report of the
American College of Cardiology/American Heart Association Task Force
on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-S73.
- Shah RR, Pillai A, Omar A, Zhao J et al. Utility of the HAS-BLED Score
in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12
Months After Drug-Eluting Stent Placement. Catheter Cardiovasc Interv
2017; 89: E99-E103.
- Alan P Jacobsen, Inbar Raber, Cian P McCarthy et al. Lifelong Aspirin
for All in the Secondary Prevention of Chronic Coronary Syndrome:
Still Sacrosanct or Is Reappraisal Warranted? Circulation. 2020 Oct
20;142(16):1579-1590. doi: 10.1161/CIRCULATIONAHA.120.045695.
- Salih Kılıç, Ahmet Çelik, Elif Çekirdekçi, et al. The Prevalence and
Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical
Practice: Results From WARFARIN-TR Study. Balkan Med J. 2019
1;36(1):17-22.
- Manes C, Giacci L, Sciartilli A, D’Alleva A, De Caterina R. Aspirin
overprescription in primary cardiovascular prevention. Thromb Res.
2006;118:471–477.
- Jeffrey J VanWormer, Aaron W Miller, Shereif H Rezkalla. Aspirin
overutilization for the primary prevention of cardiovascular disease.
Clin Epidemiol . 2014 Dec 1;6:433-40.
- Ravi
S
Hira , Kevin
Kennedy , Vijay
Nambi , et al . Frequency and
practice-level variation in inappropriate aspirin use for the primary
prevention of cardiovascular disease: insights from the National
Cardiovascular Disease Registry’s Practice Innovation and Clinical
Excellence registry. J Am Coll Cardiol. 2015 Jan 20;65(2):111-21.
- Colin
W O’Brien,
Stephen
P
Juraschek, Christina
C Wee. Prevalence of Aspirin Use for Primary Prevention of
Cardiovascular Disease in the United States: Results From the 2017
National Health Interview Survey. Ann Intern Med. 2019 Oct
15;171(8):596-598. doi: 10.7326/M19-0953. Epub 2019 Jul 23.